# Observational Study on the Efficacy and Safety of NovoSeven® During "Real-life" Usage in Germany

> **NCT00697320** · — · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 64 (actual)

## Conditions studied

- Congenital Bleeding Disorder
- Congenital FVII Deficiency
- Glanzmann's Disease
- Acquired Bleeding Disorder
- Acquired Haemophilia

## Interventions

- **DRUG:** eptacog alfa (activated)

## Key facts

- **NCT ID:** NCT00697320
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2016-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00697320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00697320, "Observational Study on the Efficacy and Safety of NovoSeven® During "Real-life" Usage in Germany". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00697320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*